Last updated: 2026-09-09 04:52:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Mirum Pharmaceuticals, Inc. (MIRM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $99.57, with a market capitalization of $6.15B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $63.23 to $130.00. This page covers its latest market performance, valuation, price trends and company information.
$6.15B | |
$98.49 | |
$130.00 | |
$6.51 | |
$100.90 | |
531.29K | |
772.63K | |
-- | |
$130.00 | |
$63.23 | |
-- | |
-- |
Mirum Pharmaceuticals, Inc. (MIRM) last closed at $100.90 as of 2026-09-08 23:31:00, unchanged from the previous close of $100.90.
During the latest regular trading session, MIRM traded between $6.51 and $130.00, with a volume of 531.29K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Mirum Pharmaceuticals, Inc. (MIRM) moved from $99.75 to $99.57, representing a decline of 0.18% ($0.18).
The stock traded between $95.61 and $101.99 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 420.92 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 54.4%
MIRM is currently trading at $99.57, placing it 54.4% of the way from its 52-week low of $63.23 to its 52-week high of $130.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 418 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Mirum Pharmaceuticals, Inc. (MIRM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.